Tramadol

Pharmacology¹

Mechanism of Action

• Tramadol is a centrally acting synthetic opioid that selectively binds to mu-opioid receptors in the CNS.
• Its analgesic activity also involves inhibiting serotonin and norepinephrine reuptake, thereby enhancing descending pain-inhibition pathways.

Active Metabolite

• Tramadol is a prodrug, an inactive compound that is metabolized into its active form.
• The liver enzyme CYP2D6 converts tramadol to M1, which has a sixfold higher affinity for the mu receptor than tramadol itself, producing stronger analgesia.
• As a result, there is significant interindividual variability in the amount of active drug produced.²
• “Poor metabolizers” with absent or reduced CYP2D6 activity will form less opioid metabolite and less analgesia
• “Ultra-rapid metabolizers” will have more active drug and thus increased opioid-like effects, including sedation and respiratory depression

Receptor Affinity

• Tramadol binds to the mu receptor less strongly than morphine, and its effects are not fully reversed by naloxone, distinguishing it from classic opioids.

Absorption

• Oral bioavailability averages ~75% for a 100 mg dose. Peak plasma concentrations of tramadol occur at 2 hours, and of M1 at 3 hours, with steady-state levels achieved within 2 days of four-times-daily dosing.

Distribution and Metabolism

• The volume of distribution is ~2.6 L/kg in males and 2.9 L/kg in females, with 20% plasma protein binding.
• Tramadol undergoes extensive hepatic metabolism via CYP2D6 and CYP3A4, involving N- and O-demethylation, glucuronidation, and sulfation.

Elimination

• Tramadol and its metabolites are primarily excreted renally, about 30% unchanged and 60% as metabolites.
• CYP2D6 poor metabolizers have higher parent drug levels but reduced M1 formation, leading to diminished analgesic response.

Systemic Effects

CNS

• Tramadol exerts analgesic effects through weak mu-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake, resulting in both opioid and monoaminergic modulation of pain pathways.³
• The active metabolite M1, formed by CYP2D6 metabolism, has up to sixfold greater affinity for the mu receptor than the parent compound, accounting for much of tramadol’s analgesic potency.³
• Tramadol can lower the seizure threshold, with seizures reported at therapeutic and supratherapeutic doses, particularly in patients on concomitant serotonergic or stimulant medications.⁴
• It can precipitate serotonin syndrome, especially when combined with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, or triptans, characterized by agitation, hyperreflexia, tremor, and hyperthermia.⁶
• CNS depression (e.g., sedation, dizziness, confusion) may occur, and effects are potentiated when tramadol is combined with alcohol, benzodiazepines, or other CNS depressants.⁶
• Unlike traditional opioids, naloxone only partially reverses tramadol’s CNS effects, as part of its activity is mediated by serotonin–norepinephrine reuptake inhibition.³
• Chronic or high-dose exposure has been linked to neurotoxic effects, including agitation, hallucinations, and in rare cases, dependence and withdrawal syndromes involving both opioid and antidepressant-like mechanisms.⁴

Cardiovascular System

• Tramadol’s enhancement of noradrenergic tone can cause mild increases in heart rate and blood pressure, though severe hypertension is rare.⁴
• In overdose or rapid intravenous administration, tachycardia, arrhythmias, and hypotension have been reported.⁶
• Long-term experimental studies suggest endothelial dysfunction and oxidative stress-related cardiac injury, although clinical correlation in humans remains limited.⁷

Respiratory System

• Compared with full opioids, tramadol causes less respiratory depression at therapeutic doses, but serious hypoventilation can occur in overdose or with coadministration of CNS depressants.⁶
• The risk of respiratory depression increases in poor CYP2D6 metabolizers, who accumulate the parent compound rather than the active M1 metabolite.³
• Respiratory compromise is especially dangerous when combined with benzodiazepines, alcohol, or other sedatives, and fatalities have been reported.⁶

Clinical Uses

Acute Pain Management

• Tramadol is approved by the U.S. Food and Drug Administration for the treatment of moderate-to-severe acute pain. It is often used for postoperative, musculoskeletal, or traumatic pain when nonopioid analgesics are inadequate.
• It provides both opioid-mediated and monoaminergic (serotonin/norepinephrine) analgesia, making it useful for mixed-type pain (e.g., nociceptive + neuropathic).
• Compared with more potent opioids, tramadol causes less respiratory depression and is preferred when a milder opioid is indicated.
• Common settings include day surgery, emergency departments, orthopedic injuries, and postdental procedures.

Chronic and Neuropathic Pain

• Tramadol is used for chronic noncancer pain that is refractory to nonopioid options such as NSAIDs, acetaminophen, or adjuvant analgesics.
• It is sometimes prescribed for neuropathic pain syndromes (e.g., diabetic peripheral neuropathy, sciatica, postherpetic neuralgia) because of its serotonin/norepinephrine reuptake inhibition, which mimics some antidepressant-like effects.
• In older adults or patients sensitive to more potent opioids, tramadol can serve as a step-2 analgesic on the World Health Organization analgesic ladder, bridging the gap between nonopioids and full opioid agonists.
• Long-term use requires careful evaluation for tolerance, dependence, and cognitive effects, particularly in elderly patients.

Off-Label Uses

• Premature ejaculation: Recommended by the American Urological Association as a second-line option for patients unresponsive to SSRIs or topical anesthetics. Clinical trials have shown improvements in ejaculatory latency with on-demand use.
• Fibromyalgia and chronic musculoskeletal pain: Used as an adjunct in select patients when first-line agents (e.g., SNRIs, pregabalin) provide incomplete relief.
• Off-label use is discouraged in populations at risk for substance use disorder or when nonopioid alternatives remain effective.
• Restless leg syndrome (RLS): Occasionally used for refractory RLS when dopamine agonists and gabapentin are ineffective. Its serotonergic and opioid actions may help reduce sensory discomfort.

Side/Adverse Effects¹

• The most common adverse effects include nausea, dizziness, pruritus (itching), constipation, vomiting, somnolence (drowsiness), and headache.
• These symptoms typically occur during the initial phase of treatment and tend to lessen during maintenance therapy.
• Tramadol-induced mania has been reported, even in patients without a prior history of bipolar disorder.
• Serious adverse reactions include profound sedation and respiratory depression, which, if severe, can be fatal.
• Adrenal insufficiency may occur and requires immediate recognition, discontinuation of tramadol, and initiation of corticosteroid therapy.
• Cardiovascular effects such as severe hypotension, syncope, and orthostatic hypotension have been documented.
• Tramadol can depress respiratory drive, leading to carbon dioxide (CO2) retention and an increase in intracranial pressure (ICP); therefore, it should be used cautiously in patients with brain tumors or elevated ICP.